Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -97.02% is 78% below its 2-year average of -54.45%, near the low end of its 2-year range (-97.02%–-32.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.28% below its 12-month average of -65.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -97.02%.
RETURN ON EQUITY (ROE)
-97.02%
RETURN ON EQUITY (ROE) AVG TTM
-65.88%
RETURN ON EQUITY (ROE) AVG 3Y
-54.45%
RETURN ON EQUITY (ROE) AVG 5Y
-54.45%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-47.28%
CURRENT VS 3Y AVG
-78.19%
CURRENT VS 5Y AVG
-78.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
-135.49%
vs the sector median at left
Boundless Bio, Inc.
Market Cap
$58.66M
Return on Equity (ROE)
-97.02%
TTM Avg
-65.88%
3Y Avg
-54.45%
5Y Avg
-54.45%
Market Cap
$57.88M
Return on Equity (ROE)
N/A
TTM Avg
-285.38%
3Y Avg
-206.98%
5Y Avg
-151.57%
Market Cap
$59.41M
Return on Equity (ROE)
-132.16%
TTM Avg
-74.56%
3Y Avg
-71.32%
5Y Avg
22.85%
Market Cap
$59.46M
Return on Equity (ROE)
-82.38%
TTM Avg
-68.06%
3Y Avg
-60.95%
5Y Avg
-49.61%
Market Cap
$57.69M
Return on Equity (ROE)
N/A
TTM Avg
71.44%
3Y Avg
1810.59%
5Y Avg
1190.90%
Market Cap
$60.22M
Return on Equity (ROE)
N/A
TTM Avg
85.37%
3Y Avg
6.44%
5Y Avg
-23.00%
Market Cap
$57.09M
Return on Equity (ROE)
-104.65%
TTM Avg
-123.21%
3Y Avg
-45.49%
5Y Avg
-1.96%
Market Cap
$56.98M
Return on Equity (ROE)
-72.55%
TTM Avg
6.13%
3Y Avg
236.20%
5Y Avg
116.25%
Market Cap
$60.49M
Return on Equity (ROE)
-30.21%
TTM Avg
-215.14%
3Y Avg
-180.32%
5Y Avg
47.11%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | $58.66M | -97.02% | -65.88% | -54.45% | -54.45% |
| PDS Biotechnology Corporation (PDSB)vs › | $57.88M | N/A | -285.38% | -206.98% | -151.57% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $59.41M | -132.16% | -74.56% | -71.32% | 22.85% |
| Adicet Bio, Inc. (ACET)vs › | $59.46M | -82.38% | -68.06% | -60.95% | -49.61% |
| MiNK Therapeutics, Inc. (INKT)vs › | $57.69M | N/A | 71.44% | 1810.59% | 1190.90% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | N/A | 85.37% | 6.44% | -23.00% |
| Talphera, Inc. (TLPH)vs › | $57.09M | -104.65% | -123.21% | -45.49% | -1.96% |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | -72.55% | 6.13% | 236.20% | 116.25% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -30.21% | -215.14% | -180.32% | 47.11% |
| Fractyl Health, Inc. (GUTS)vs › | $60.98M | N/A | -866.00% | -422.47% | -312.54% |
ROE
-97.0%
ROA
-37.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -97.02% |
| 2026-03-31 | -64.82% |
| 2025-12-31 | -58.99% |
| 2025-09-30 | -56.06% |
| 2025-06-30 | -52.48% |
| 2025-03-31 | -48.09% |
| 2024-12-31 | -43.39% |
| 2024-09-30 | -36.99% |
| 2024-06-30 | -32.20% |
| 2019-09-30 | -107.51% |
| 2019-06-30 | -87.11% |
| 2019-03-31 | -81.69% |
| 2018-12-31 | -68.79% |
| 2018-09-30 | -85.65% |
| 2018-06-30 | -69.98% |
| 2018-03-31 | -63.14% |
| 2017-12-31 | -137.34% |
| 2017-09-30 | -105.23% |
| 2017-06-30 | -97.89% |
